title: In vitro induction of anterior gradient-2-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses as a potential therapy for colorectal cancer.
abstract: Anterior gradient-2 (AGR2) promotes tumor growth, cell migration, and cellular transformation, and is one of the specific mRNA markers for circulating tumor cells in patients with gastrointestinal cancer. We investigated the feasibility of AGR2 as a potent antigen for tumor immunotherapy against colorectal cancer (CRC) cells using dendritic cells (DCs) transduced with a recombinant adenovirus harboring the AGR2 gene (AdAGR2). DCs transduced with a recombinant adenovirus encoding the AGR2 gene (AdAGR2/DCs) were characterized. These genetically-modified DCs expressed AGR2 mRNA as well as AGR2 protein at a multiplicity of infection of 1,000 without any significant alterations in DC viability and cytokine secretion (IL-10 and IL-12p70) compared with unmodified DCs as a control. In addition, AdAGR2 transduction did not impair DC maturation, but enhanced expression of HLA-DR, CD80, and CD86. AdAGR2/DCs augmented the number of IFN-γ-secreting T-cells and elicited potent AGR2-specific cytotoxic T lymphocytes capable of lysing AGR2-expressing CRC cell lines. These results suggest that AGR2 act as a potentially important antigen for immunotherapy against CRC in clinical applications.
authors.affiliation: Research Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Korea.
authors.forename: Hyun Ju
authors.initials: HJ
authors.lastname: Lee
authors.forename: Cheol Yi
authors.initials: CY
authors.lastname: Hong
authors.forename: Mi Hyun
authors.initials: MH
authors.lastname: Kim
authors.forename: Youn Kyung
authors.initials: YK
authors.lastname: Lee
authors.forename: Thanh Nhan
authors.initials: TN
authors.lastname: Nguyen-Pham
authors.forename: Byoung Chul
authors.initials: BC
authors.lastname: Park
authors.forename: Deok Hwan
authors.initials: DH
authors.lastname: Yang
authors.forename: Ik Joo
authors.initials: IJ
authors.lastname: Chung
authors.forename: Hyeoung Joon
authors.initials: HJ
authors.lastname: Kim
authors.forename: Je Jung
authors.initials: JJ
authors.lastname: Lee
mesh_terms: D000256:Adenoviridae; D017951:Antigen Presentation / Q000235:genetics; D000951:Antigens, Neoplasm / Q000276:immunology; D014408:Biomarkers, Tumor / Q000276:immunology; D002277:Carcinoma / Q000628:therapy*; D045744:Cell Line, Tumor; D015179:Colorectal Neoplasms / Q000628:therapy*; D003602:Cytotoxicity, Immunologic / Q000235:genetics; D003713:Dendritic Cells / Q000276:immunology; D006801:Humans; D016219:Immunotherapy, Adoptive; D007371:Interferon-gamma / Q000378:metabolism; D008213:Lymphocyte Activation / Q000235:genetics; D009088:Mucoproteins; D015513:Oncogene Proteins; D011506:Proteins / Q000235:genetics / Q000378:metabolism*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014161:Transduction, Genetic; D019076:Transgenes / Q000235:genetics
chemical_list: C502296:AGR2 protein, human; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D009088:Mucoproteins; D015513:Oncogene Proteins; D011506:Proteins; D007371:Interferon-gamma
references.citation: Curr Opin Biotechnol. 1999 Oct;10(5):440-7
references.pmid: 10508634
references.citation: Cancer Detect Prev. 2008;32(3):236-50
references.pmid: 18801625
references.citation: Nat Med. 1995 Dec;1(12):1297-302
references.pmid: 7489412
references.citation: J Gen Virol. 1990 Oct;71 ( Pt 10):2425-31
references.pmid: 2172456
references.citation: Cancer Res. 2008 Oct 1;68(19):7811-8
references.pmid: 18829536
references.citation: Gastroenterology. 2006 Sep;131(3):925-33
references.pmid: 16952561
references.citation: Prostate Cancer Prostatic Dis. 2007;10(3):293-300
references.pmid: 17457305
references.citation: Cancer Res. 2005 May 1;65(9):3796-805
references.pmid: 15867376
references.citation: Gene Ther. 1997 Oct;4(10):1023-8
references.pmid: 9415307
references.citation: Vaccine. 2006 Apr 5;24(15):2860-8
references.pmid: 16443309
references.citation: Exp Hematol. 1997 Jan;25(1):39-44
references.pmid: 8989905
references.citation: Eur J Immunol. 1999 Mar;29(3):964-72
references.pmid: 10092101
references.citation: Cancer Res. 2008 Jul 15;68(14):5972-8
references.pmid: 18632653
references.citation: J Immunol Methods. 1991 Dec 15;145(1-2):185-92
references.pmid: 1765650
references.citation: Nat Med. 1998 Mar;4(3):328-32
references.pmid: 9500607
references.citation: Mech Dev. 1998 Mar;72(1-2):115-30
references.pmid: 9533957
references.citation: J Virol. 1999 Dec;73(12):10245-53
references.pmid: 10559341
references.citation: J Clin Lab Anal. 1991;5(5):344-66
references.pmid: 1941355
references.citation: Immunol Rev. 2002 Oct;188:177-82
references.pmid: 12445291
references.citation: Oncology. 2005;68(2-3):163-70
references.pmid: 16006753
references.citation: J Exp Med. 1997 Oct 6;186(7):1177-82
references.pmid: 9314567
references.citation: Nat Rev Immunol. 2005 Apr;5(4):296-306
references.pmid: 15803149
references.citation: Scand J Immunol. 1993 Dec;38(6):529-34
references.pmid: 8256110
references.citation: J Immunol. 2007 Feb 15;178(4):1975-9
references.pmid: 17277099
references.citation: Immunol Today. 1997 Apr;18(4):175-82
references.pmid: 9136454
references.citation: Gene Ther. 2000 Jul;7(13):1112-20
references.pmid: 10918477
references.citation: Cancer Gene Ther. 1998 Nov-Dec;5(6):350-6
references.pmid: 9917089
references.citation: J Exp Med. 1997 Oct 20;186(8):1247-56
references.pmid: 9334364